Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Funding

    NextGenMicrofluidics

    Funding programme, Funded by: JOSNNEUM RESEARCH Forschungsgesellschaft mbH, sb_search.searchresult.label.programSubmissionDate: 30/09/2023
    https://www.bio-pro.de/en/service/funding/nextgenmicrofluidics-1
  • Press release - 01/04/2022

    FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer

    On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
  • Press release - 30/03/2022

    CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

    CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
  • Press release - 29/03/2022

    Biocopy presents "ValidaTe" – A novel ultra-fast screening technology

    ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-presents-validate-novel-ultra-fast-screening-technology
  • Press release - 21/03/2022

    BMBF funds Heidelberg Junior Research Group for 3D Bioprinting Project

    Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bmbf-funds-heidelberg-junior-research-group-3d-bioprinting-project
  • Press release - 14/03/2022

    Do gut bacteria influence treatment success of CAR-T cell therapies?

    Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
  • Press release - 10/03/2022

    Innovation Day Upper Rhine provides cross-border knowledge transfer

    Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
  • Press release - 01/03/2022

    CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

    The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
  • Press release - 03/02/2022

    The 5G-OR Project is a Winner of the joint Franco-German Program for the Development of innovative Applications for 5G private Networks

    5G-OR is one of the 4 winning projects jointly selected by the Federal Ministry of Economics and Climate Action in Germany and the Ministry of Economy, Finance and Relaunch in France for the call “Technical developments and application ecosystems for 5G private networks”. The joint Franco-German 5G-OR project takes up the challenge in the healthcare domain.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/5g-or-project-winner-joint-franco-german-program-development-innovative-applications-5g-private-networks
  • Press release - 14/12/2021

    EU regulation approved: G-BA collaborates on European health technology assessment

    Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-regulation-approved-g-ba-collaborates-european-health-technology-assessment
  • Press release - 09/12/2021

    New research project in mathematical oncology

    A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
  • Press release - 23/11/2021

    Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response

    At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
  • Funding

    Digital Europe Programme

    Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://www.gesundheitsindustrie-bw.de/en/database/funding/digital-europe-programme
  • Funding

    Digital Europe Programme

    Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://www.bio-pro.de/en/service/funding/digital-europe-programme
  • Press release - 19/10/2021

    Gips Schüle Research Award for three scientists from the University of Stuttgart

    Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gips-schuele-research-award-three-scientists-university-stuttgart
  • Expert interview - 31/08/2021 A coloured circular representation of different types of scenarios: 1a-c: Gradual evolution of the healthcare system, 2 a-b: Healthcare system change arises from cultural evolution, 3a-c: Healthcare system change arises from innovative technologies and cultural awareness change, 4a-b: Technology-driven healthcare system change.

    Health Data Scenarios - many possibilities for the future?

    The digitization of healthcare is progressing slowly but steadily. In addition to simple telemedical applications, data such as electronic patient records are forming the basis of digitization. The ‘Health Data Scenarios’ project aims to model the future of healthcare data by using scenarios. Lucas Scherdel, Healthcare Innovation Director at DayOne, and Dr. Alexander Fink, founder and CEO of ScMI AG, explain how this will work.

    https://www.gesundheitsindustrie-bw.de/en/article/news/health-data-scenarios-many-possibilities-future
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
  • Press release - 16/08/2021

    Heidelberg is calling for life sciences start-ups

    As a dominant part of southern Germany’s life-science industry hub, Heidelberg will soon have a life-science startup incubator of its own. BioLabs, the premier US network of managed co-working lab space, will open its first German branch in the Heidelberg Innovation Park (hip). On August 16, representatives of city and state governments, BioLabs and the life-science industry celebrated the Heidelberg BioLabs groundbreaking.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-calling-life-sciences-start-ups
  • Workplace of the future - 10/08/2021 Prototype image of a body support system that fixes a person at the abdomen and hips

    Intelligent body support system for surgery staff

    Operating room staff often spend hours in strenuous postures, which has a significant impact on concentration and quality of work. While operating room equipment is increasingly networked, state-of-the-art medical technology, conditions for operating room staff trail way behind. The start-up company Hellstern medical offers an effective solution for serious pain, fatigue and incorrect interventions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-body-support-system-surgery-staff
  • Press release - 06/07/2021

    High-throughput metabolic profiling of single cells

    Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-throughput-metabolic-profiling-single-cells
  • Funding

    Horizone Europe

    Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://www.gesundheitsindustrie-bw.de/en/database/funding/horizone-europe
  • Funding

    Horizone Europe

    Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://www.bio-pro.de/en/service/funding/horizone-europe
  • Article - 22/06/2021 Ausschnitt aus der Software von living brain. Patienten erlernen anhand von Übungen mit VR im kritischen Zeitfenster Alltagsaufgaben effektiv.

    Using virtual reality in the clinic to rehabilitate patients with cognitive disorders

    Outdated and inadequate methods of neurological rehabilitation are still being used for patients with neurological diseases or injuries – and what’s more, the treatment is usually too late. This is because cognitive training is especially important in the critical phases when the brain is particularly plastic. The Heidelberg-based company living brain proves that early treatment is possible using an extremely innovative method – with concentrated…

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-virtual-reality-clinic-rehabilitate-patients-cognitive-disorders
  • Press release - 10/06/2021

    Nose2Brain – Active substances without detour through the nose into the brain

    Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
  • Final chord of the EU-project Smart SMEs - 31/05/2021 Smart_SMEs_Logo.png

    Building a sustainable network for natural fibre-based SMEs in the Alpine Space

    The European project Smart SMEs came successfully to its end in May 2021 with the final conference, which attracted participants from different parts of Europe.

    https://www.bio-pro.de/en/information/press-release/building-sustainable-network-natural-fibre-based-smes-alpine-space
  • Press release - 26/05/2021

    Memetis continues its path to become a technology leader in Shape Memory driven miniature valving – Fluid-o-Tech S.r.l. invests an undisclosed amount to support memetis’ growth and development

    The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/memetis-continues-its-path-become-technology-leader-shape-memory-driven-miniature-valving-fluid-o-tech-srl-invests-undisclosed-a
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines - a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Health Data Scenarios

    Health Data Scenarios

    Data generated by the healthcare system has enormous potential for improving the quality of patient-centered care. As part of the Health Data Scenarios project, Basel Area Business & Innovation worked with numerous experts from industry and academia in 2020 to develop ten scenarios of what future health data ecosystems could look like. These scenarios are now being discussed and validated together with experts and opinion leaders from…

    https://www.bio-pro.de/en/projects/Completed-projects/health-data-scenarios
  • Press release - 17/05/2021

    New findings in genome research

    The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-genome-research

Page 5 / 7

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • eine Seite zurück
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search